Achieving Guideline Control with New Pharmacotherapies: Albumin-Binding by Acylation of Insulin and GLP-1
Over the last 15 years, it has become apparent that substantial reduction in the risk of micro- and macro-vascular complications follows from intensified treatment regimens in type 1 and 2 diabetes [1–3]. In simple terms, reducing HbA1c from 9% to 7% in patients with type 1 diabetes leads to an approximate halving of the risk of angiopathyrelated diabetic complications [1, 2].
KeywordsHuman Insulin American Diabetes Association Insulin Glargine Insulin Aspart Insulin Detemir
Unable to display preview. Download preview PDF.
- 1.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.Google Scholar
- 2.The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.Google Scholar
- 3.UK prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.Google Scholar
- 10.Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in-vivo. Biochem J 1995;312:725–731.PubMedGoogle Scholar
- 13.Galloway JA, Spradlin CT, Howey DC, Dupre J.-Intrasubject differences in pharmacokinetic and pharmacodynamic responses: the immutable problem of present-day treatment. In Diabetes 1985, Serrano-Rios M, Lefebvre PJ, Eds. New York, Excerpta Medica, 1986:877–886.Google Scholar
- 15.Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall M-A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47:622–629.CrossRefPubMedGoogle Scholar
- 16.Hermansen K, Davies M, Derezinski T, Martinez G, Clauson P, Home PA. 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269–1274.CrossRefPubMedGoogle Scholar